Hegseth Orders Review Of US Force Posture In Europe, Warns NATO Laggards Of Consequences

Lilly's Next-Gen Weight-Loss Drug Clears Trial With Near-Bariatric Surgery Results Eli Lilly reported positive Phase 3 results for its next-generation obesity drug, retatrutide, which delivered weight-loss results on par with those of bariatric surgery. In the TRIUMPH-1 trial, overweight adults, but without diabetes, achieved meaningful weight loss across all tested doses after 80 weeks: 12 mg dose: average weight loss of 70.3 pounds, or 28.3% of body weight. 9 mg dose: average weight loss of 64.4 pounds, or 25.9%. 4 mg dose: average weight loss of 47.2 pounds, or 19% Ahead of the results,...

Micro-Cap 'War Unicorn' Merlin Soars After Advancing AI Pilot For C-130 Military Plane Aerospace and defense technology firm Merlin jumped in premarket trading after announcing that its AI-powered autonomous flight software for the C-130J Super Hercules cargo plane, developed with U.S. Special Operations Command, is moving toward formal testing. Merlin wrote in a press release earlier that its AI-powered autonomous flight software has "successfully completed" the critical design review for the C-130J, adding the "milestone positions the program to enter a structured formal test campaign, including aircraft-level testing, reflecting a disciplined...

Sam Altman Pushes Plan For Backdoor Government Backstop By Handing Out Small Equity Stake To Americans Back in November, amid mounting speculation that OpenAI's massive cash burn was massively unsustainable in light of the $1.4 trillion of funding commitments by the AI company, which in turn has sparked the biggest capex flood in modern history all on the hope that the company's promised payments will be made good, OpenAI CFO Sarah Friar sparked a market selloff when amid an admission that OpenAI was “looking for an ecosystem of banks [and]...